Afobazol tab 10mg 60 pc

Description

Composition
Active substance:
1 tablet contains: fabomotizole (fabomotizole dihydrochloride) – 5 mg and 10 mg.
Excipients:
Potato starch – 48 mg, microcrystalline cellulose – 40 mg (for the dosage 5 mg) and 35 mg (for the dosage of 10 mg), lactose monohydrate – 48.5 mg of middle povidone (polyvinylpyrrolidone middle molecular medicine, Kollidon 25) – 7 mg magnesium stearate – 1.5 mg.
Description:
Tablets white or white with kremovatam color, Valium chamfered.
Product form:
Tablets of 5 mg or 10 mg.
10, 20, 25 or 30 tablets in blisters.
30, 50, 100 or 120 tablets per polymeric jars.
Each jar or 3, 5 or 10 contour packs of 10 pills, or 1, 2, 3, 4 or 6, contour packs of 20 tablets, or a 2 or 4-outline packages of 25 tablets, or 1, 2, 3 or 4 Contoured packaging of 30 tablets together with instructions for use placed in a pile of cardboard.
Contraindications
Individual intolerance to the drug. Galactose intolerance, lactase deficiency or glucose-galactose malabsorption. Pregnancy, lactation. Children up to age 18 years.
Dosage
10 mg
Indications
Afobazol used in adults with anxiety: generalized anxiety disorder, neurasthenia, adjustment disorder, in patients with various medical conditions (asthma, irritable bowel syndrome, systemic lupus erythematosus, ischemic heart disease, hypertension, arrhythmias), dermatological, oncological, etc. . diseases. In the treatment of sleep disorders associated with anxiety, neuro dystonia, premenstrual syndrome, alcohol withdrawal syndrome, in order to facilitate the syndrome of “cancellation” for smoking cessation.
Interaction with other drugs
Afobazol does not react with ethanol and does not affect the hypnotic effect of thiopental. It enhances the anticonvulsant effect of carbamazepine. Causes increased anxiolytic effect of diazepam.
Overdose
When a large overdose and intoxication may develop sedation and increased sleepiness without manifestations of muscle relaxation. As used emergency caffeine 20% solution in vials of 1.0 ml 2-3 times a day subcutaneously.
pharmachologic effect
Pharmacological group:
Antianxiety drug (tranquilizer).
Pharmacodynamics:
Afobazol – selective non-benzodiazepine anxiolytic. By acting on the sigma-1 receptors in brain nerve cells Afobazol stabilizes GABA / benzodiazepine receptors and restores their sensitivity to endogenous mediators of inhibition. Afobazol also increases the bio-energy potential of neurons and has a neuroprotective effect: restores and protects nerve cells.
Effect of the drug advantageously implemented as a combination of anxiolytic (antianxiety) and lung stimulatory (activating) effect. Afobazol reduces or eliminates anxiety (concern, foreboding, fear), irritability, tension (fearfulness, tearfulness, anxiety, inability to relax, insomnia, fear), depressed mood, somatic symptoms of anxiety (muscle, sensory, cardiovascular, respiratory , gastrointestinal symptoms), vegetative disorders (dry mouth, sweating, dizziness), cognitive disorders (difficulty concentrating, impaired memory), including: arising from stress disorders (disorders of adaptation). Especially shows use of the drug in patients with predominantly asthenic personality traits as alarming suspiciousness, uncertainty, increased vulnerability and emotional lability, emotsionalnostressovym propensity for reactions. The effect of the drug develops 5-7 days of treatment. The maximum effect is achieved by the end of 4 weeks of treatment and persist after the end of treatment an average of 1-2 weeks. Afobazol causes muscle weakness, somnolence, and has no negative influence on the concentration and memory. In its application is not formed addiction, drug dependence syndrome and do not develop “cancel.”
Pharmacokinetics:
After oral administration Afobazol well and rapidly absorbed from the gastrointestinal tract.
Maximum plasma concentrations (Cmax) – 0,130 + 0,073 ug / ml; time to reach maximum concentration (Tmax) – 0.85 + 0.13 hours.
Metabolism: Afobazol subjected to “first pass effect” through the liver, the major directions of the metabolism is the hydroxylation of the aromatic ring of the benzimidazole cycle and the oxidation of the morpholine moiety.
Afobazol intensively distributed over well vascularised organs, it is typical for rapid transfer of a central pool (plasma) into the peripheral (highly vascularized organs and tissues).
Afobazol half-period ingestion of 0.82 + 0.54 hours. Short half-life due to intense biotransformation of the drug and fast from the blood plasma distribution in organs and tissues. The drug is excreted mainly as metabolites and partially unchanged in the urine and feces.
Pregnancy and breast-feeding
Use of the drug is contraindicated in pregnancy Afobazol®. If necessary, use during lactation should stop breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
Allergic reactions.
Seldom – a headache, which usually resolves on its own and does not require discontinuation of therapy.
special instructions
Effects on ability to drive vehicles, mechanisms:
The drug has no negative influence on the driving of vehicles and the performance of potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
Store at a temperature not higher than 25 C. Keep out of reach of children.
Dosing and Administration
Administered orally, after meals.
The optimal single dose – 10 mg; DSA – 30 mg distributed for 3 doses throughout the day. Duration of the course of the drug is – 2-4 weeks. If necessary, by a doctor’s recommendation, the daily dose may be increased to 60 mg and the treatment duration up to 3 months.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist